Literature DB >> 16973833

In vitro expanded cells contributing to rapid severe combined immunodeficient repopulation activity are CD34+38-33+90+45RA-.

Katrien Vanheusden1, Stefanie Van Coppernolle, Magda De Smedt, Jean Plum, Bart Vandekerckhove.   

Abstract

Expansion of hematopoietic stem cells could be used clinically to shorten the prolonged aplastic phase after umbilical cord blood (UCB) transplantation. In this report, we investigated rapid severe combined immunodeficient (SCID) repopulating activity (rSRA) 2 weeks after transplantation of CD34(+) UCB cells cultured with serum on MS5 stromal cells and in serum- and stroma-free cultures. Various subpopulations obtained after culture were studied for rSRA. CD34(+) expansion cultures resulted in vast expansion of CD45(+) and CD34(+) cells. Independent of the culture method, only the CD34(+)33(+)38(-) fraction of the cultured cells contained rSRA. Subsequently, we subfractionated the CD34(+)38(-) fraction using stem cell markers CD45RA and CD90. In vitro differentiation cultures showed CD34(+) expansion in both CD45RA(-) and CD90(+) cultures, whereas little increase in CD34(+) cells was observed in both CD45RA(+) and CD90(-) cultures. By four-color flow cytometry, we could demonstrate that CD34(+)38(-)45RA(-) and CD34(+)38(-)90(+) cell populations were largely overlapping. Both populations were able to reconstitute SCID/nonobese diabetic mice at 2 weeks, indicating that these cells contained rSRA activity. In contrast, CD34(+)38(-)45RA(+) or CD34(+)38(-)90(-) cells contributed only marginally to rSRA. Similar results were obtained when cells were injected intrafemorally, suggesting that the lack of reconstitution was not due to homing defects. In conclusion, we show that after in vitro expansion, rSRA is mediated by CD34(+)38(-)90(+)45RA(-) cells. All other cell fractions have limited reconstitutive potential, mainly because the cells have lost stem cell activity rather than because of homing defects. These findings can be used clinically to assess the rSRA of cultured stem cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973833     DOI: 10.1634/stemcells.2006-0256

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks.

Authors:  T Holmes; F Yan; K-H Ko; R Nordon; E Song; T A O'Brien; A Dolnikov
Journal:  Cell Prolif       Date:  2012-03-20       Impact factor: 6.831

2.  Ex vivo expansion and long-term hematopoietic reconstitution ability of sorted CD34+CD59+ cells from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Juan Xiao; Bing Han; Yong-Ji Wu; Yu-ping Zhong; Wan-ling Sun
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

3.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

4.  Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) mice.

Authors:  Lisa J Giassi; Todd Pearson; Leonard D Shultz; Joseph Laning; Kristin Biber; Morey Kraus; Bruce A Woda; Madelyn R Schmidt; Robert T Woodland; Aldo A Rossini; Dale L Greiner
Journal:  Exp Biol Med (Maywood)       Date:  2008-08

5.  Expansion on stromal cells preserves the undifferentiated state of human hematopoietic stem cells despite compromised reconstitution ability.

Authors:  Mattias Magnusson; Maria I Sierra; Rajkumar Sasidharan; Sacha L Prashad; Melissa Romero; Pamela Saarikoski; Ben Van Handel; Andy Huang; Xinmin Li; Hanna K A Mikkola
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

Review 6.  Ethical issues relating the the banking of umbilical cord blood in Mexico.

Authors:  V Moises Serrano-Delgado; Barbara Novello-Garza; Edith Valdez-Martinez
Journal:  BMC Med Ethics       Date:  2009-08-14       Impact factor: 2.652

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.